Shionogi has completed its acquisition of global rights to Radicava and Radicava ORS, two edaravone formulations approved to treat amyotrophic lateral sclerosis (ALS), from Tanabe Pharma, finalizing a deal announced late last year. When it signed the agreement, Tanabe said it would establish a U.S.-based company to…